In The Literature
Med Oncol

Targeted Next-Generation Sequencing Identified Novel Mutations in Triple-Negative Myeloproliferative Neoplasms


Enhanced Calreticulin Expression in Red Cells of Polycythemia Vera Patients Harboring the JAK2V617F Mutation

J Clin Invest

Downregulation of GATA1 Drives Impaired Hematopoiesis in Primary Myelofibrosis


Polycythemia Vera Management and Challenges in the Community Health Setting

J Natl Compr Canc Netw

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

Intern Med J

A Case-Based Discussion of Clinical Problems in the Management of Patients Treated With Ruxolitinib for Myelofibrosis

Clin Adv Hematol Oncol

Prevention and Management of Thrombosis in Myeloproliferative Neoplasms

Curr Opin Hematol

Management of Venous Thromboembolism in Myeloproliferative Neoplasms


Differences in Treatment Goals and Perception of Symptom Burden Between Patients With Myeloproliferative Neoplasms (MPNs) and Hematologists/Oncologists in the United States: Findings from the MPN Landmark Survey

Leuk Lymphoma

Clinical Use of Ruxolitinib in an Academic Medical Center in Unselected Patients With Myeloproliferative Neoplasms not on Clinical Study

Leuk Res

Markers of Iron Deficiency in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy

Ther Adv Hematol

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Pathophysiology and Molecular Mechanisms of Disease

Biol Blood Marrow Transplant

The Impact of Splenectomy in Myelofibrosis Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Ann Hematol

Novel Hematological Parameters for the Evaluation of Patients With Myeloproliferative Neoplasms: the Immature Platelet and Reticulocyte Fractions


No Correlation of Intensity of Phlebotomy Regimen With Risk of Thrombosis in Polycythemia Vera: Evidence From ECLAP and CYTO-PV Clinical Trials

Ann Vasc Surg

Medical Management of Extensive Arterial Thromboembolism in a Patient With Essential Thrombocythemia and Warfarin Failure

Blood Cancer J

Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations


Myeloproliferative Neoplasm Stem Cells

J Hematol Oncol

Long-Term Treatment with Ruxolitinib for Patients With Myelofibrosis: 5-Year Update From the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial

Br J Haematol

Progenitor Genotyping Reveals a Complex Clonal Architecture in a Subset of CALR-Mutated Myeloproliferative Neoplasms

Blood Cancer J

The Role of the Extracellular Matrix in Primary Myelofibrosis

Br J Haematol

Approach to Patients With Essential Thrombocythemia and Very High Platelet Counts: What is the Evidence for Treatment?

Am J Hematol

Polycythemia Vera and Essential Thrombocythemia: 2017 Update on Diagnosis, Risk-Stratification, and Management

Ann Lab Med

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

J Clin Pathol

A Novel Molecular Assay Using Hybridisation Probes and Melt Curve Analysis for CALR Exon 9 Mutation Detection in Myeloproliferative Neoplasms

Clin Med (Lond)

Myocardial Infarction With Proximal Occlusion of the Left Anterior Descending Coronary Artery in a 22-Year-Old Patient With Polycythaemia Vera


Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes

Nature Scientific Rep

Neutrophil Extracellular Trap Formation and Circulating Nucleosomes in Patients With Chronic Myeloproliferative Neoplasms


Emerging Treatments for Classical Myeloproliferative Neoplasms


Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis

Blood Cancer J

Bone Marrow Fibrosis Grade is an Independent Risk Factor for Overall Survival in Patients With Primary Myelofibrosis

Curr Opin Hematol

'Janus Kinase-ing' Up the Treatment of Primary Myelofibrosis

Int J Lab Hematol

Proliferative Characteristics of Philadelphia-Negative Myeloproliferative Neoplasms: Clinical Implications


Aberrant Let7a/HMGA2 Signaling Activity Associated With Unique Clinical Phenotypes in JAK2-Mutated Myeloproliferative Neoplasms

Ann Hematol

Programmed Cell Death-1 Pathway Inhibition in Myeloid Malignancies: Implications for Myeloproliferative Neoplasms

World J Cardiol

Hematological Disorders and Pulmonary Hypertension

PLoS One

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment

Expert Opin Investig Drugs

Investigational Distone Deacetylase Inhibitors (HDACi) in Myeloproliferative Neoplasms

Ann Diagn Pathol

Cutaneous Myeloid Dendritic Cell Dyscrasia: A Cutaneous Clonal Monocytosis Associated with Chronic Myeloproliferative Disorders and Peripheral Blood Monocytosis


Evaluation of Bone Marrow Morphology is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients

Blood Cancer J

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Risk Factors for Recurrences in a Cohort of 181 Patients

Clin Epidemiol

The Danish National Chronic Myeloid Neoplasia Registry

Biomed Res Int

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches

BMC Cancer

Myeloproliferative Neoplasms (MPNs) Have a Significant Impact on Patients’ Overall Health and Productivity

Osteoporosis International

Bone Mineral Density and Microarchitecture in Patients With Essential Thrombocythemia and Polycythemia Vera

Annuals of Hematology

Management of Extreme Thrombocytosis in Myeloproliferative Neoplasms: An International Physician Survey

Modern Pathology

The Myeloproliferative Neoplasms, Unclassifiable: Clinical and Pathological Considerations

PLoS One

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes

Mutation Research/Reviews in Mutation Research

Mutations of Myelodysplastic Syndromes (MDS): An Update

Journal of Blood Medicine

Ruxolitinib in the Treatment of Polycythemia Vera: Patient Selection and Special Considerations

Blood Reviews

The 2016 revision of WHO classification of myeloproliferative neoplasms


Activation of the Thrombopoietin Receptor by Mutant Calreticulin in CALR-Mutant Myeloproliferative Neoplasms

Current Hematologic Malignancy Report

The Use of Anagrelide in Myeloproliferative Neoplasms, With Focus on Essential Thrombocythemia

Clinical Lymphoma, Myeloma & Leukemia

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms

American Society of Clinical Oncology

Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden

Journal of Medicinal Chemistry

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

Clinical Lymphoma, Myeloma & Leukemia

How to Treat Essential Thrombocythemia and Polycythemia Vera

click me